Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Truist Securities Adjusts Eli Lilly and Co.'s Price Target to $301 from $262, Keeps Buy Rating

11/24/2021 | 11:52am EST


© MT Newswires 2021
All news about ELI LILLY AND COMPANY
01/25GLOBAL MARKETS LIVE : Credit Suisse, Unilever, Nvidia, Tesla, American Express...
01/25WALL STREET STOCK EXCHANGE : A roller-coaster week as Fed decision looms
01/25MARKETSCREENER’S WORLD PRESS REVIEW : January 25, 2022
01/24US FDA Restricts Use of Eli Lilly, Regeneron's COVID-19 Treatments
MT
01/24FDA to Restrict Monoclonal Antibodies Manufactured by Eli Lilly, Regeneron Pharmaceutic..
MT
01/24Morgan Stanley Adjusts Eli Lilly and Co.'s Price Target to $272 from $275, Keeps Overwe..
MT
01/21Innovent and Eli Lilly and Company Announces Final Clinical Results and Biomarker Analy..
CI
01/21GSK, Vir ramping up U.S. output of COVID antibody drug
RE
01/21Alzheimer's patient groups protest U.S. Medicare coverage proposal limiting use of new ..
RE
01/21DZ Bank Upgrades Eli Lilly and Co. to Buy From Hold; Price Target is $291
MT
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 28 205 M - -
Net income 2021 6 216 M - -
Net Debt 2021 12 037 M - -
P/E ratio 2021 37,0x
Yield 2021 1,40%
Capitalization 216 B 216 B -
EV / Sales 2021 8,07x
EV / Sales 2022 8,02x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 237,86 $
Average target price 285,18 $
Spread / Average Target 19,9%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY-13.89%215 642
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
NOVO NORDISK A/S-15.89%213 450